Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

Bevacizumab

  • You have access
    Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy
    SERIKA MATSUOKA, HIRONORI FUJII, HIROTOSHI IIHARA, KOICHI OHATA, CHIEMI HIROSE, DAICHI WATANABE, SHIORI SADAKA, SHIGERU KIYAMA, AKITAKA MAKIYAMA, TAKAO TAKAHASHI, RYO KOBAYASHI, NOBUHISA MATSUHASHI and AKIO SUZUKI
    Anticancer Research May 2023, 43 (5) 2351-2357; DOI: https://doi.org/10.21873/anticanres.16400
  • Open Access
    Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment
    SATOSHI FUKUDA, YUSUKE NIISATO, MIKI TSUJI, SOMA FUKUDA, YUYA HAGIWARA, TSUBASA ONODA, HIROSUMI SUZUKI, YOSHITAKA TANGE, TAKESHI YAMADA, YOSHIYUKI YAMAMOTO and TOSHIKAZU MORIWAKI
    Anticancer Research May 2023, 43 (5) 2085-2090; DOI: https://doi.org/10.21873/anticanres.16369
  • Open Access
    Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
    GINTARAS ZALESKIS, MARTYNAS TALAIKIS, DAINIUS CHARACIEJUS, VINCAS URBONAS, PAULIUS BOSAS, ADAS DARINSKAS, LAVIJA ZIBUTYTE, LUKAS SIMKUS, ZILVINAS SURVILA, JURGITA JURSENAITE and MARGARITA ZVIRBLE
    Anticancer Research March 2023, 43 (3) 1065-1072; DOI: https://doi.org/10.21873/anticanres.16251
  • Open Access
    Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
    MARINA ABE, TADAHIRO SHOJI, YOHEI CHIBA, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, FUMIAKI TAKAHASHI, TAKESHI AIDA and TSUKASA BABA
    Anticancer Research March 2023, 43 (3) 1265-1272; DOI: https://doi.org/10.21873/anticanres.16273
  • You have access
    Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
    AKIHIRO TAMIYA, MOTOHIRO TAMIYA, YUJI INAGAKI, YOSHIHIKO TANIGUCHI, KEIKO NAKAO, YOSHINOBU MATSUDA, TAKAHISA KAWAMURA, KEI KUNIMASA, TAKAKO INOUE, KAZUMI NISHINO and KYOICHI OKISHIO
    Anticancer Research March 2023, 43 (3) 1325-1330; DOI: https://doi.org/10.21873/anticanres.16280
  • You have access
    Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
    YEN-HAO CHEN, YEN-YANG CHEN, JING-HOUNG WANG and CHAO-HUNG HUNG
    Anticancer Research March 2023, 43 (3) 1377-1384; DOI: https://doi.org/10.21873/anticanres.16286
  • You have access
    Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer
    KOJI TAKADA, SHINICHIRO KASHIWAGI, NOZOMI IIMORI, RIKA KOUHASHI, AKIMICHI YABUMOTO, WATARU GOTO, YUKA ASANO, YUKIE TAUCHI, KANA OGISAWA, TAMAMI MORISAKI, MASATSUNE SHIBUTANI, HIROAKI TANAKA and KIYOSHI MAEDA
    Anticancer Research February 2023, 43 (2) 849-856; DOI: https://doi.org/10.21873/anticanres.16227
  • You have access
    Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture
    TATSUNORI MIYATA, KAZUHIRO SUGI, TAICHI HORINO, ASUKA ONO, YOSHIYUKI TAGAYASU, DAICHI NOMOTO, MITSUHIRO INOUE, TAKAO MIZUMOTO, TATSUO KUBOTA, ERIKO YANAGIDA, TOSHIHIKO MURAYAMA, NOBUTOMO MIYANARI and HIDEO BABA
    Anticancer Research February 2023, 43 (2) 943-947; DOI: https://doi.org/10.21873/anticanres.16239
  • You have access
    Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study
    ALEXANDRE BEIGE, FRANÇOIS GHIRINGHELLI, JULIE LECUELLE, CAROLINE TRUNTZER, GILLES TRUC, JULIE VINCENT, WALID FARAH, FRANÇOIS BORSOTTI, IRINA MAZILU and SILVIA MIHAELA ILIE
    Anticancer Research December 2022, 42 (12) 5847-5858; DOI: https://doi.org/10.21873/anticanres.16093
  • You have access
    Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors
    JI HYUN PARK, HYUN SEOK LEE, JIN WOO CHOI, SO DUG LIM, HYEON KANG KOH, KYUNG RAE CHO, JOON CHO, YOUNG-CHO KOH and SO YOUNG YOON
    Anticancer Research December 2022, 42 (12) 6091-6098; DOI: https://doi.org/10.21873/anticanres.16121

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 11
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire